yes, that is a possibility. On the other hand if VYVGART treatment for CIDP patients from Argenx is accepted by the market within next two to three years, CSL will have to scramble around to find replacement revenue in many millions/billions.
CSL Chart, page-1096
-
- There are more pages in this discussion • 14 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add CSL (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$300.26 |
Change
-1.400(0.46%) |
Mkt cap ! $145.3B | |||
| Open | High | Low | Value | Volume |
| $303.31 | $303.47 | $299.56 | $148.6M | 498.1K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 276 | $300.19 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $300.34 | 1250 | 1 |
View Market Depth
| Last trade - 16.10pm 13/09/2024 (20 minute delay) ? |
| CSL (ASX) Chart |